[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640930":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":46,"id":50,"slug":19,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":19,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Michigan State University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Speech Study","EXPERIMENTAL","Single arm study: All speech conditions are administered.",[13],"Behavioral: Behavioral speech strategies + speech amplification",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":19},"BEHAVIORAL","Behavioral speech strategies + speech amplification",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Thea Knowles, PhD","CONTACT","517-353-6401","thea@msu.edu",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","East Lansing","Michigan","48823","United States",{"type":34,"coordinates":35},"Point",[36,37],-84.48387,42.73698,{"lat":37,"lon":36},[40,41],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":22,"role":42,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"type":42,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Thea Knowles","Assistant Professor",[47],{"name":48,"class":49},"National Institute on Deafness and Other Communication Disorders (NIDCD)","NIH","100640930",false,"NCT07599696","Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements","Speech Amplification Devices for Parkinson and Related Diseases: Talker- and Technology-Driven Enhancements","Inclusion Criteria:\n\n* Dominant speakers of North American English\n* Have received a neurologist's diagnosis of Parkinson disease or parkinsonism (e.g., PSP\u002FMSA\u002FPSP)\n* Present with changes in their speech\u002Fvoice\n\nExclusion Criteria:\n\n* History of any other speech, language, or neurological concern other than Parkinson\u002Fparkinsonism.\n* Uncorrected hearing loss that exceeds a threshold of 40 dB HL in more than one ear (as per baseline screening audiometry) and\u002For use of a cochlear implant.","ALL","50 Years",{"count":59,"type":60},100,"ESTIMATED","INTERVENTIONAL",[63],"NA","The proposed research aims to investigate the use of speech amplification devices as a potential treatment option for people with Parkinson's disease and related disorders who exhibit hypophonia, a voice disorder that affects over half of those with Parkinson's disease. By characterizing the acoustic and perceptual effects of speech amplification and identifying ways to optimize outcomes through talker- and device-specific enhancements, this project seeks to develop personalized, evidence-based treatment options for hypophonia. The current proposal will move this effort forward by systematically eliciting and modifying speech amplification device output that leverage both behavioral and technological approaches.",[66,67],"Parkinson Disease","Atypical Parkinsonism",[69,70,71,72,73,74,75,76,77,78],"speech","Parkinson's disease","atypical parkinsonism","speech acoustics","speech-language pathology","hypophonia","voice","voice disorders","speech disorders","dysarthria","2026-05-14",{"date":81,"type":82},"2026-05-20","ACTUAL",{"date":84,"type":82},"2024-03-01",{"date":86,"type":60},"2028-05-31",{"name":5,"class":6},1]